New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 8, 2014
10:28 EDTVRTX, KPTI, EBKDY, VSTM, ZINC, ZBRA, TFM, HOS, BRKR, BECNOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Beacon Roofing (BECN) downgraded to Market Perform from Outperform at William Blair... Bruker (BRKR) downgraded to Neutral from Buy at ISI Group... Erste Group Bank (EBKDY) downgraded to Hold from Buy at Deutsche Bank... Hornbeck Offshore (HOS) downgraded to Equal Weight from Overweight at Stephens... Horsehead Holding (ZINC) downgraded to Market Perform at FBR Capital... Karyopharm (KPTI) downgraded to Perform from Outperform at Oppenheimer... The Fresh Market (TFM) downgraded to Sell from Neutral at Goldman... Verastem (VSTM) downgraded to Perform from Outperform at Oppenheimer... Vertex (VRTX) downgraded to Perform from Outperform at Oppenheimer... Zebra Technologies (ZBRA) downgraded to In-Line from Outperform at Imperial Capital.
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2015
08:46 EDTBECNBeacon Roofing price target raised to $49 from $40 at Baird
Baird raised its price target on Beacon Roofing to $49 from $40 following better than expected Q4 results and guidance. The firm cited signs of improvement in residential re-roofing, gross margin trends and continued excellent expense discipline. Baird reiterated its Outperform rating on Beacon Roofing shares.
November 24, 2015
10:56 EDTBECNBeacon Roofing says majority of company's acquisitions tuck-in
10:55 EDTBECNBeacon Roofing says environment 'fertile' for acquisitions
Subscribe for More Information
10:19 EDTBECNBeacon Roofing says November trending ahead of last year
Subscribe for More Information
10:12 EDTBECNBeacon Roofing sees FY16 EPS 'in the range of $1.80,' consensus $1.81
Notes that current FY16 analyst consensus is "a wide range," with a high of $2.00 and a low of $1.60.
10:11 EDTBECNBeacon Roofing sees FY16 revenue $3.8B-$4B, consensus $3.88B
Subscribe for More Information
08:02 EDTBECNBeacon Roofing reports Q4 adjusted EPS 75c, consensus 69c
Subscribe for More Information
November 23, 2015
08:34 EDTVRTXVertex names Michael J. Parini EVP, chief legal officer
Subscribe for More Information
November 20, 2015
10:34 EDTVRTXVertex approval in Europe to bring gradual uptake, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff says Vertex Pharmaceuticals must now gain reimbursement in each individual country after the European Union approved Orkambi as expected. The approval will ultimately add around 12,000 homozygous F508del cystic fibrosis patients appropriate for the drug, but uptake will be gradual and dependent on the pace of reimbursement. He reiterates an Overweight rating on Vertex with a $180 price target.
05:36 EDTVRTXVertex receives EU approval for Orkambi
Subscribe for More Information
November 19, 2015
16:15 EDTTFMThe Fresh Market sees FY15 adjusted EPS $1.55-$1.60, consensus $1.60
Subscribe for More Information
16:13 EDTTFMThe Fresh Market reports Q3 adjusted EPS 23c, consensus 22c
Subscribe for More Information
08:59 EDTTFMThe Fresh Market volatility elevated into Q3 and outlook
Subscribe for More Information
November 18, 2015
13:27 EDTBECNBeacon Roofing management to meet with William Blair
Subscribe for More Information
05:41 EDTVRTXVertex receives 2 EU approvals for Kalydeco
Vertex Pharmaceuticals announced that the European Commission has approved expansion of the indication for Kalydeco to include children ages 2 to 5 with cystic fibrosis, or CF, who have one of nine gating mutations in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene and to include people with CF ages 18 and older who have an R117H mutation. Ivacaftor was previously approved in the European Union, or EU, for use in people with CF ages 6 and older who have one of nine gating mutations. In Europe, approximately 125 children with CF ages 2 to 5 have one of the nine gating mutations included in today's approval and approximately 350 adults with CF have an R117H mutation. Vertex will now begin the country-by-country reimbursement approval processes for each new indication.
November 16, 2015
07:16 EDTVRTXHayman Capital gives quarterly update on stakes
NEW STAKES: Impax (IPXL), CF Industries (CF), GW Pharmaceuticals (GWPH), ProNAi Therapeutics (DNAI). INCREASED STAKES: BioMarin (BMRN), NMI Holdings (NMIH), Vertex (VRTX), Endo (ENDP). DECREASED STAKES: Mylan (MYL). LIQUIDATED STAKES: Perrigo (PRGO), Oasis Petroleum (OAS), Whiting Petroleum (WLL), Newfield Exploration (NFX), SM Energy (SM).

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use